Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech develops drug candidates for hard to treat cancers and viruses, led by Annamycin. It last closed at $7.74 on Nov 20, down 2.40% on the day. The next earnings report for MBRX is expected around Thu, Mar 18, 2027. For the quarter ended Sep 2026, MBRX reported EPS of -$9.59 on revenue of $0. Over its last 8 reports the stock moved an average of 4.8% the session after earnings.
Key Stats
Last 12 monthsNot reported for this period.
From MBRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →- Every upgrade, downgrade and initiation as it happens
- Every price target change, raised or cut
- Consensus rating with the average, high and low targets
- Each firm's full rating history on MBRX
Technical AnalysisPrices may be delayed
The stock is 4% below its 20 day and 18% below its 50 day average. It is 345% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 46). The nearest support is the swing low (Nov 2) at $7.65, and the nearest resistance the Pivot at $7.90.
| RSI (14) | 46.17 | Middle of its range | Neutral |
| MACD | -0.43 | Above its signal line | Bullish |
| Stochastic | 36.4 | Middle of its range | Neutral |
| ADX (14) | 14.1 | No clear trend | |
| Williams %R | -52.1 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -25.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −11.0% | Change over 10 sessions | Bearish |
| ATR (14) | $0.96 | Typical daily range, 12.4% of price |
| RSI (14) | 31.56 | Weak, oversold below 30 | Neutral |
| MACD | -14.89 | Above its signal line | Bullish |
| Stochastic | 29.0 | Middle of its range | Neutral |
| ADX (14) | 25.3 | Trending down | |
| Williams %R | -75.5 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -60.2 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −45.9% | Change over 10 sessions | Bearish |
| ATR (14) | $7.73 | Typical daily range, 99.9% of price |
What happened before
See how MBRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How MBRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2005.
Whale Options FlowPrices may be delayed
90DNo whale options trades in MBRX in the last 90 days.
MBRX Institutional Ownership
Full report →- ▲11 buying vs 5 selling
- ▲Held by funds +40.1 pts
- ▲Funds holding +3
- ●No superinvestor moves
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 23 | 20 | +15.0% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 59.5% | 19.4% | +40.1 pts |
| New / increased | 7 / 4 | 6 / 8 | −21.4% |
| Reduced / sold out | 2 / 3 | 0 / 7 | −28.6% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
MBRX Insider Trading
All filings →| Trade date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 23, 2025 | Walter V KlempCEO and President | Buy | 675,675 | $0.37 | $250K |
| Jun 23, 2025 | Jonathan P. FosterCFO | Buy | 270,270 | $0.37 | $100K |
From SEC Form 4 filings by MBRX's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.
AI Auto Pilots
Paper tradingStreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether MBRX is in one of them and how their past MBRX trades turned out.
MBRX News Tone and PricePrices may be delayed
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered MBRX in an article yet. Here's the latest on the wider market.
- Moleculin Strengthens Global Intellectual Property Portfolio Around Annamycin, Secures Korean Patent Allowance
- Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout
- Moleculin Secures Australian Patent for Annamycin Formulation Technology
- Preclinical Data Show Annamycin Makes Pancreatic Cancer Responsive to Checkpoint Inhibitors, Opening a Combination Path with Immunotherapies
- Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
- Moleculin Completes Dosing Patients in Part A of Pivotal MIRACLE Trial; Comprehensive Data Readout on Track for Q1 2027
About Moleculin Biotech
Moleculin Biotech is a pharmaceutical development company based in Houston, Texas, that develops drug candidates for cancer and certain viruses. Its lead candidate, Annamycin, is an anthracycline chemotherapy agent being studied for relapsed or refractory acute myeloid leukemia and for soft tissue sarcoma that has spread to the lungs. Much of its research is carried out with academic investigators, including at MD Anderson Cancer Center in Houston.
- Headquarters
- Houston, TX